These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 15621751

  • 21. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
    Alemany M, Levin J.
    Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
    [Abstract] [Full Text] [Related]

  • 22. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS, Ignoffo RJ.
    Cancer Pract; 2001 Jun; 9(3):155-7. PubMed ID: 11879303
    [No Abstract] [Full Text] [Related]

  • 23. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
    Sahara N, Takeshita A, Kobayashi M, Shigeno K, Nakamura S, Shinjo K, Naito K, Maekawa M, Horii T, Ohnishi K, Kitamura K, Naoe T, Hayash H, Ohno R.
    Leuk Lymphoma; 2004 May; 45(5):987-95. PubMed ID: 15291359
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
    Ni J, Chen G, Shen Z, Li X, Liu H, Huang Y, Fang Z, Chen S, Wang Z, Chen L.
    Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):250-3. PubMed ID: 15622757
    [Abstract] [Full Text] [Related]

  • 28. Arsenic trioxide.
    Litzow MR.
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [Abstract] [Full Text] [Related]

  • 29. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Petit A, Delaune A, Falluel-Morel A, Goullé JP, Vannier JP, Dubus I, Vasse M.
    Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
    [Abstract] [Full Text] [Related]

  • 30. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
    Leung J, Pang A, Yuen WH, Kwong YL, Tse EW.
    Blood; 2007 Jan 15; 109(2):740-6. PubMed ID: 16968895
    [Abstract] [Full Text] [Related]

  • 31. As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
    Fu GH, Wang Y, Xi YH, Guo ZW, Liu XB, Bai SZ, Yang BF, Chen GQ.
    J Drug Target; 2005 May 15; 13(4):235-43. PubMed ID: 16051535
    [Abstract] [Full Text] [Related]

  • 32. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
    Bernardini S, Nuccetelli M, Noguera NI, Bellincampi L, Lunghi P, Bonati A, Mann K, Miller WH, Federici G, Lo Coco F.
    Ann Hematol; 2006 Oct 15; 85(10):681-7. PubMed ID: 16733740
    [Abstract] [Full Text] [Related]

  • 33. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T, Westervelt P, Hess JL.
    Mod Pathol; 2000 Sep 15; 13(9):954-61. PubMed ID: 11007035
    [Abstract] [Full Text] [Related]

  • 34. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin, Huang MJ, Chang IY, Lin WY, Sheu YT.
    Leuk Lymphoma; 2000 Jun 15; 38(1-2):195-8. PubMed ID: 10811463
    [Abstract] [Full Text] [Related]

  • 35. [In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
    Tang W, Chen G, Shen Z, Chen L, Shi X, Jia P, Shi G, Ni J, Chen S, Wang Z.
    Zhonghua Xue Ye Xue Za Zhi; 1997 Dec 15; 18(12):623-6. PubMed ID: 15625759
    [Abstract] [Full Text] [Related]

  • 36. MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
    Liang H, Li X, Wang L, Yu S, Xu Z, Gu Y, Pan Z, Li T, Hu M, Cui H, Liu X, Zhang Y, Xu C, Guo R, Lu Y, Yang B, Shan H.
    Cell Physiol Biochem; 2013 Dec 15; 32(6):1818-29. PubMed ID: 24356076
    [Abstract] [Full Text] [Related]

  • 37. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E, Schultheis B, Büchner T, Hehlmann R.
    Dtsch Med Wochenschr; 2007 Feb 16; 132(7):330-6. PubMed ID: 17286223
    [No Abstract] [Full Text] [Related]

  • 38. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
    Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z.
    Leukemia; 2001 May 16; 15(5):735-41. PubMed ID: 11368433
    [Abstract] [Full Text] [Related]

  • 39. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
    Cai X, Jia P, Shi X.
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jul 16; 19(7):339-41. PubMed ID: 11189513
    [Abstract] [Full Text] [Related]

  • 40. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L, Mohassel L.
    Am J Health Syst Pharm; 2009 Nov 01; 66(21):1913-8. PubMed ID: 19850784
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.